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The need for special ethical principles in a scien-
tiﬁc society is the same as the need for ethical
principles in society as a whole. They are mutu-
ally beneﬁcial. They help make our relationships
mutually pleasant and productive. A professional
society is a voluntary, cooperative organization,
and those who must conform to its rules are also
those who beneﬁt from the conformity of others.
Each has a stake in maintaining general compli-
ance. (Stuart Altmann, Chair, Ethics Committee,
Animal Behavior Society, http://www.ethicsweb.
ca/codes/coe2.htm)
This issue of Value in Health contains ISPOR’s
Code of Ethics for Researchers, together with an
explanatory article by the Chair of the ISPOR Code
of Ethics Task Force. ISPOR’s Board of Directors
approved the Code in January 2003. This editorial
addresses both the Code and its accompanying
article.
ISPOR was formed as an amalgamation of a US
and a European group. It draws its membership
from over 44 countries; holds annual conferences in
Europe, the United States and most recently a con-
ference in the Asia-Paciﬁc area; and it has regional
chapters in at least three countries and student
chapters in the United States, Canada, and Scot-
land. ISPOR is becoming a truly international soci-
ety, embracing members from countries with diverse
political systems and cultures.
Rich professional networks are available in the
United States and Europe, but the rest of the world
is less fortunate. Through its conferences, work-
shops, and task forces, ISPOR has done a sterling
job in providing education and thoughtful analyses
of controversial technical issues such as economic
modeling practices and retrospective analysis of
databases. Local and regional chapters will also
help some members to maintain a current knowl-
edge of research practice.
At the heart of ISPOR is the science of pharma-
coeconomics and outcomes research, which has
brought together a diverse group of disciplines
including economics, epidemiology, pharmacy,
medicine, social sciences, and others. The term
“pharmacoeconomics” was coined in the late
1980s, and the science has been consolidated and
disseminated by peer-reviewed journals including
PharmacoEconomics (launched in 1992) and the
ofﬁcial journal of ISPOR, Value in Health (launched
in 1998). Along with exponential development of
the science and rapid growth in membership came
the need for the Society to develop and propound its
philosophy on many issues including ethical stand-
ards for researchers.
The Task Force is to be congratulated for produc-
ing a Code of Ethics. The need for a Code of Ethics
is not self-evident (many organizations do not have
one) and its purpose is not stated. Nevertheless, the
purposes of a Code of Ethics have been stated else-
where (http://www.calsca.com/ethics_lscabc.htm)
as:
• Deﬁning accepted/acceptable behaviors;
• Promoting high standards of practice;
• Providing a benchmark for members to use for
self-evaluation;
• Establishing a framework for professional
behavior and responsibilities;
• Being a vehicle for occupational identity; and
• Being a mark of occupational maturity.
The new Code contains a concise summary of views
that were presumably debated within the Task
Force. The Code comprises six sections, each con-
taining 4 to 11 bullet points. Most of the content is
addressed to individual members but the last section
is designed for ISPOR as an organization. Perhaps
the Code would be more aptly named “ISPOR’s
Code of Ethics.”
Relationships
The Code begins (appropriately) by listing the con-
stituencies of ISPOR’s members, including patients,
payers, practitioners, government groups, research-
ers, students, employers, and clients. These group-
ings are not mutually exclusive and individuals may
belong to several at once. Although “ethics” is not
deﬁned explicitly, the Code deals with relationships
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between individuals such as doctor/patient and
researcher/student and relationships between
individuals and institutions. It does not mention
broader relationships such as those between privi-
leged and underprivileged groups or any ensuing
ethical dilemmas or responsibilities.
Research Practices
Under “research practices” it spells out the applica-
tions of basic honesty applied to experimentation
and reporting of ﬁndings. Responsibilities to report
unethical practices are not mentioned.
Currency of Knowledge
The Code declares a need to “maintain a current
knowledge of research practice.” This laudable aim
may seem challenging to members who live in coun-
tries with inadequate libraries and limited budgets
for training and overseas travel, although Internet
access to library facilities is improving this situation
rapidly and online training is available (albeit
expensive).
Sponsorship
Sponsorship issues are particularly relevant to an
organization such as ISPOR, which draws much of
its membership from researchers in private indus-
try, universities, and consultancy ﬁrms. Commer-
cial sponsors including the pharmaceutical
industry understandably do not want negative
ﬁndings promulgated, although simple honesty
demands it. Ultimately, patients pay the price if
this information is withheld. Unfortunately, despite
intensive debate since a seminal article was pub-
lished over a decade ago [1], some sponsors still
attempt to restrict dissemination of information [2]
or “ﬁne tune” it to present it in the most favorable
light. Value in Health could give the Code teeth by
refusing to publish any article for which the con-
tract between sponsors and researchers restricted
the researchers’ control over study design, imple-
mentation, or dissemination of results, including
the right to publish the research results without
prejudice.
Communication
The Code contains a useful section on publication
and dissemination of research and a detailed draft
code of ethics for medical editors has been pub-
lished recently in the United Kingdom [3]. Given
that much of pharmacoeconomic research is com-
missioned speciﬁcally for marketing purposes,
should ISPOR’s code of ethics extend beyond
research to marketing practices? The ultimate cost
of unethical behavior by medical researchers and/or
marketers is public distrust of research-based med-
icines. Recent evidence shows that over half of Brit-
ish general practices offer complementary medicine
[4] and similar ﬁndings are likely elsewhere. The
price for the credibility gap is paid by patients in
failed unscientiﬁc therapies, resultant delays in
accessing evidence-based therapies, unanticipated
adverse events [5,6], and opportunity cost. It is also
paid by researchers in the form of public skepticism
about medical information, particularly that prom-
ulgated by the pharmaceutical industry, even when
that information is demonstrably of the highest
quality.
Authorship
Given the ever-increasing career requirement for
publication, it is timely for the Code to restate some
of the principles of the International Committee of
Journal Editors (the Vancouver Group) with regard
to authorship entitlement [7]. Value in Health, like
other major peer-reviewed medical journals, could
consider providing a checklist for declaring author-
ship. This may go some way toward blocking inap-
propriate authorship, although ultimately this is a
matter of personal integrity, because academic and
research institutions count publications to help
assess eligibility for promotion, and most institu-
tions leave authorship to individual conscience.
Corporate Obligations
The Code also addresses ISPOR as an organization.
It states that ISPOR should publicize its Code of
Ethics (accomplished in this issue of Value in
Health), strive for balance in sponsorship, issue its
own statement of objectivity and autonomy from
sponsors, peer review its published papers (double-
blind peer review is current practice in Value in
Health), and maintain a board and committees (pre-
sumably including ad hoc task forces) that are rep-
resentative of its membership.
Gaps in the Code
There are some signiﬁcant gaps in the Code and in
the process of its development.
Process
One might expect an international society to
develop its code of ethics with a broad interna-
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tional representation. It was surprising therefore to
discover that the eminent members of the task force
all had US addresses. Perhaps this explains why the
Code declares that “. . . federal and state laws gov-
erning protection of medical information, such as
HIPAA, must be strictly observed.” This injunction
is meaningless for those members who work out-
side US jurisdictions. Given the US orientation of
the Code, one might wonder how well some of
its determinations apply in non-US environments,
especially those with a very different sociopolitical
base.
One might also expect broad representation, a
transparent consultative process, substantial peer
review, and advice from an ethicist. The Code
should state that it was made available to ISPOR
members before its approval by the Board and it
should acknowledge input from an ethicist (if any).
The Committee included the disciplines of phar-
macy and economics, and also employers including
government, managed care, and the pharmaceutical
industry, but scientiﬁc publishing was not repre-
sented, even though a substantial section of the
Code (appropriately) is concerned with publication
issues.
Conﬂicts
What should happen when there is a conﬂict
between the ethical code and workplace con-
straints? In this situation, employees of universities,
hospitals, consultancy companies, and the pharma-
ceutical industry may feel bound ﬁrst to their
employer and then to the ethical codes of ISPOR
and other professional bodies to which they belong.
But should the ﬁrst duty of an employee be to the
employer or to broader ethical principles? If the
former, why do we need a Code of Ethics?
What support, if any, will ISPOR provide when
one of us perceives a conﬂict between broad ethical
principles and our own employer or a client or
sponsor? Could ISPOR provide an independent
advisory role to its members, perhaps through an
elected committee? Or is this a matter that is best
left to other professional organizations? What proc-
esses (if any) could ISPOR set in place to support its
members in ethical behavior, especially those who
are not buffered by major institutions such as uni-
versities and multinationals?
Breadth
In 1992 an informal group of philosophers, ethi-
cists, historians, and scientists enunciated a meth-
odology for developing and assessing ethical codes
[8]. The “Toronto Resolution” begins:
Living in a world in which all forms of life are
interdependent, we recognize that human activity
since the scientiﬁc revolution now threatens
much of the life on our planet. This threat stems
in part from reckless exploitation of the earth’s
resources and massive pollution of the biosphere
by humankind, exacerbated by rampant mil-
itarism . . . scientists and scholars have a partic-
ular responsibility to society for the effects of
their work . . .
The group developed principles that should be
held in common by codes of ethics for scientists
including:
“A code should indicate speciﬁc measures
designed to ensure that signatories adhere to its
principles.” We are told, however, that ISPOR’s
Code is “advisory not mandatory” and that ISPOR
“is not particularly interested in serving as an arbi-
ter of complaints or as a licensure board.” To the
best of my knowledge, ISPOR has no formal proc-
ess for providing advice or for adjudicating on eth-
ical dilemmas that may confront members, and no
mechanism to apply sanctions, such as suspension
of membership for breaches of the Code.
“A code should oppose prejudice with respect to
sex, religion, national or ethnic origin, age, sexual
preference, color, or physical or mental disability.”
These universal principles should be mentioned
in ISPOR’s Code, given that most institutional
employers embrace them, at least in the West.
“A code should be widely disseminated through
the school and university curricula, to educate the
rising generations, as well as practicing scientists
and scholars, about their emerging responsibilities.”
Given that many members play signiﬁcant parts in
tertiary education and postgraduate training, it
would be helpful for ISPOR’s Code to encourage
and inspire education and debate about the key eth-
ical issues that confront members.
Finally, ISPOR is well placed to take an active
role in promoting discussion about international
ethical issues in health care, such as government and
multinational policies/strategies that minimize the
supply of medicines to those who most need them:
global equity (e.g., the AIDS epidemic in sub-
Saharan Africa [9,10]); distributional issues ensuing
from the desire of multinationals to maximize prof-
its, often with little consideration for the needs of
developing countries; overconsumption (of medi-
cines, food, and other consumer goods [11]) by a
small proportion of privileged nations in a world
afﬂicted by poverty [12]; and related environmental
issues pertaining to survival of the biosphere. If we
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are concerned as a group about such critical issues,
they should be in our Code of Ethics. If they are not,
we could be seen to be merely looking after the
interests of our careers and professions.
The Code has been stated and approved. All that
is required is for us to attempt to live up to our
stated ideals (hopefully with ISPOR’s support)
. . . and to broaden and deepen our Code of Ethics.
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